In early 2013, MetaMax, Ltd, a participant of the Skolkovo Innovation Centre, can start the clinical trials of its drug for the treatment of intestine cancer, Dmitry Popov, managing partner of Maxwell Biotech Venture Fund, told the journalists on Wednesday. MetaMax is a portfolio company of Maxwell Biotech.
“The company is finishing the preclinical studies and preparing the registration dossier. We plan to initiate the clinical trials of the product at the end of this year or in the beginning of the next year”. – Popov said.
He noted that MetaMax works on the basis of a platform technology, which will make it possible to develop a set of drugs for the treatment of oncologic and other diseases.
MetaMax is a biotechnological company, founded in 2010 for the development and bringing to the Russian market of innovation drugs in the sphere of the diagnostics and treatment of the most wide spread and dangerous human diseases. MetaMax is a participant of a technological platform Medicine of the Future and since August 2011 it is a participant of the Skolkovo Innovation Centre.
Maxwell Biotech Venture Fund is a closed mutual investment fund of high risk (venture) investments, managed by Maxwell Asset Management, Ltd, specializing in investments in biotechnological companies of different development stages. The fund was set up with the participation of RVC.
Source: RIA Novosti